Aiforia Technologies Oy Class A · OMXHEX:AIFORIA
Aiforia Technologies Oy Class A — H1 2025 Earnings Presentation
24 slides from Aiforia Technologies Oy Class A's earnings presentation, Aug 28, 2025
Slide 1: Aiforia - AI for image analysis
. @ aifor Al for image analysis
Slide 2: Expansion continues, driven by commercial and regulatory advancements
Expansion continues, driven by commercial and regulatory advancements Half-year Financial report for January 1 - June 30, 2025 Aiforia Technologies Plc August 28, 2025
Slide 3: Today's agenda
Today’s agenda 01. Highlights of the first half of 2025 Jukka Tapaninen CEO 02. Financial review 03. Strategy execution 04. Q&A Veli-Matti Parkkonen CFO August 28, 2025 | Half-year Financial Report, January 1 - June 30, 2025 3
Slide 4: H1 2025 highlights
H1 2025 highlights The demand for Aiforia’s AI-assisted image analysis solutions was strong in the first half of 2025. The order book increased by 58% compared to same period last year and totaled EUR 5.1 million. Aiforia’s strong market position as a well-known supplier was reflected in new clinical
Slide 5: Recent clinical deals and collaborations
Recent clinical deals and collaborations Nantes University Hospital, France ● 2-year contract Mayo Clinic Sardinia Region, Italy ● Multi-year contract ● Breast cancer diagnostics ● Breast and prostate cancer diagnostics ● +70 pathologists using Aiforia® Platform in translational research The Lombard
Slide 6: Investments in product development have led to Aiforia's strengthened market position
Investments in product development have led to Aiforia’s strengthened market position ● Aiforia continued investing in product development. Gross investments in H1/2025 amounted to EUR 3.6 million (2.6). ● Developed new AI models and user interfaces for more efficient case-level review and reporting
Slide 7: Aiforia secured IVDR certification in February 2025
Aiforia secured IVDR certification in February 2025 The certification confirms that Aiforia’s Quality Management System complies with the requirements of the IVD Regulation, and enables Aiforia to bring an expanded portfolio of AI models to the European market. The certification was granted by a notified
Slide 8: Financial review
2 Financial review August 28, 2025 | Half-year Financial Report, January 1 - June 30, 2025 8
Slide 9: H1 2025 results in brief
H1 2025 results in brief 18% Order book grew 58% to EUR 5,113 (3,235) thousand Group revenue increased by +2% to EUR 1,395 (1,372) thousand EUR 3,679 (2,686) thousand investment mainly in product development Finland EBITDA improved to EUR –3,014 (-4,198) thousand 14% EBIT improved to EUR –5,403 (-6,
Slide 10: H1/2025: Revenue and order book
H1/2025: Revenue and order book Revenue Order book EUR, thousand EUR, thousand 1500 +2% 6000 +58% 1.4 1.4 5.1 5000 0.9 1000 0.6 4000 0.9 3.2 3000 1.0 3,235 4.2 500 2000 0.8 1000 2.2 0.5 0 0 H1/2024 H1/2025 H1/2024 H1/2025 Clinical Non-clinical Clinical Non-clinical Revenue consisted of sales of Aifo
Slide 11: Fixed costs are stable and trimmed
Fixed costs are stable and trimmed Fixed costs MEUR 18 16.5 16 15.4 15.2 73* 14 65* 75* 8.0 12 6.6 8.1 10 8 7.8 7.7 6 75* 69* 4.1 3.7 8.8 8.5 4 7.1 2 3.7 4.0 0 2022 2023 2024 2024 H1 2025 H1 other OPEX Employee costs** *FTE’s **employee costs include R&D activations and are w/o share based incentive
Slide 12: Strategy execution
aiforia 3 Strategy execution
Slide 13: Market opportunity
Market opportunity Population in relation to the number of … with no reduction of sample Pathologists Per Million pathologists¹ volumes in sight Estimated global cancer increases cases 2020-20404 Rising rates of disease like cancer, .. 2.0% CAGR 30% increase in cancer 28.9 m rates in the US in past
Slide 14: Adoption of AI in pathology is accelerating
Adoption of AI in pathology is accelerating AI-supported diagnosis Microscope Report for the clinician Tissue sample Scanner Image upload treating the patient Use of AI Any type of biological Majority of scanner Image is transferred to Benefits and result: sample or staining is and file formats are PA
Slide 15: Key competitive advantages
Key competitive advantages AI TECHNOLOGY LEADERSHIP Pioneer in providing commercial AI training tools for pathologists since 2018 Aiforia platform enables development of both diagnostic and predictive AI models Continuous product development to leverage new technologies, such as foundation models. S
Slide 16: Aiforia continues to expand our best-in-class Clinical Suites
Aiforia continues to expand our best-in-class Clinical Suites Aiforia® Lung Cancer Aiforia® Colon Suite: Suite: PD-L1* QuantCRC (prognostic AI model) UPCOMING: ® Aiforia Breast Cancer Suite: ER*, PR*, Ki67*, Aiforia® Gastric Suite HER2, Grading* Aiforia® Prostate Cancer Aiforia® Lymph Node Suite: Gl
Slide 17: Aiforia will provide solutions for up to ~60% of histopathology samples
Aiforia will provide solutions for up to ~60% of histopathology samples with pipeline modules, and >80% of all samples by 2030 DIRECTIONAL 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Gastrointestinal Breast GU (Prostate) Lung Lymphoid Key: Dermatopathology Gynecologic Head & Neck Soft Tissue & Bone
Slide 18: Tenders Won
Aiforia has consistently won an increasing number of tenders since 2021, cementing their position as a leader in AI for clinical digital pathology Year of Year Tender Win Rate 100% Aiforia tender win rate to date 5 •2021: Mayo Clinic was first tender won 5 (H1/2025) following pivot to clinical offeri
Slide 19: Short and longer-term growth drivers enable continued maximization of opportunity
Short and longer-term growth drivers enable continued maximization of opportunity as the market matures Longer-term Growth Drivers 2030+ Short-term Growth Drivers To 2030 Global Prognostic Pharma: Maximize Grow Elevate User Markets: Applications: Partner to Opportunity Clinical Experience: Capitaliz
Slide 20: Q&A
4 Q&A 20
Slide 21: For more information
For more Investor Relations Contacts information Jukka Tapaninen, CEO jukka.tapaninen@aiforia.com, +33 61 041 6686 www. investors.aiforia.com ir@aiforia.com Veli-Matti Parkkonen, CFO veli-matti.parkkonen@aiforia.com, +358 40 500 9878
Slide 22: Financial reports are available after release
➡ Financial reports are available after release at https://investors.aiforia.com/ August 28, 2025 | Half-year Financial Report, January 1 - June 30, 2025 22
Slide 23: Disclaimer
Disclaimer It should be noted that Aiforia and its business are exposed to various risks and uncertainties, and certain statements herein which are not historical facts, including without limitation, those regarding expectations for market growth and developments; expectations for growth and profitab
Slide 24: aiforia.com
. @ aifor Al for image analysis 24